Majid Vakilynejad
Majid Vakilynejad
Global Head of Modeling and Simulation (in a major pharmaceutical company)
Verified email at
Cited by
Cited by
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial
CF Burant, P Viswanathan, J Marcinak, C Cao, M Vakilynejad, B Xie, ...
The Lancet 379 (9824), 1403-1411, 2012
dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy
DC Metz, M Vakily, T Dixit, D Mulford
Alimentary pharmacology & therapeutics 29 (9), 928-937, 2009
Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled …
M Vakily, W Zhang, J Wu, SN Atkinson, D Mulford
Current medical research and opinion 25 (3), 627-638, 2009
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK‐875: results from a double‐blind, placebo‐controlled single oral dose rising …
H Naik, M Vakilynejad, J Wu, P Viswanathan, N Dote, T Higuchi, E Leifke
The Journal of Clinical Pharmacology 52 (7), 1007-1016, 2012
A multiple‐ascending‐dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK‐875, in subjects with type 2 diabetes
E Leifke, H Naik, J Wu, P Viswanathan, D Demanno, M Kipnes, ...
Clinical Pharmacology & Therapeutics 92 (1), 29-39, 2012
Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs
R Mehvar, DR Brocks, M Vakily
Clinical pharmacokinetics 41, 533-558, 2002
Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump …
RD Lee, M Vakily, D Mulford, J Wu, SN Atkinson
Alimentary pharmacology & therapeutics 29 (8), 824-833, 2009
Stereoselective dissolution of propranolol hydrochloride from hydroxypropyl methylcellulose matrices
SP Duddu, M Vakilynejad, F Jamali, DJW Grant
Pharmaceutical research 10, 1648-1653, 1993
Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury
FS Wolenski, AZX Zhu, M Johnson, S Yu, Y Moriya, T Ebihara, ...
Toxicological Sciences 157 (1), 50-61, 2017
The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats
M Vakily, B Corrigan, F Jamali
Pharmaceutical research 12, 1652-1657, 1995
Prediction of nephropathy in type 2 diabetes: an analysis of the ACCORD trial applying machine learning techniques
V Rodriguez‐Romero, RF Bergstrom, BS Decker, G Lahu, M Vakilynejad, ...
Clinical and translational science 12 (5), 519-528, 2019
Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis
M Vakily, F Amer, MJ Kukulka, N Andhivarothai
The Journal of Clinical Pharmacology 45 (10), 1179-1186, 2005
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape
E Schuck, T Bohnert, A Chakravarty, V Damian-Iordache, C Gibson, ...
The AAPS journal 17, 462-473, 2015
Lansoprazole regimens that sustain intragastric pH> 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages
DC Metz, F Amer, B Hunt, M Vakily, MJ Kukulka, N Samra
Alimentary pharmacology & therapeutics 23 (7), 985-995, 2006
Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double …
M Vakily, RD Lee, J Wu, L Gunawardhana, D Mulford
Clinical drug investigation 29, 35-50, 2009
Stereoselective pharmacokinetics and pharmacodynamics of anti-asthma agents
M Vakily, R Mehvar, D Brocks
Annals of pharmacotherapy 36 (4), 693-701, 2002
Rapid, sensitive and direct chiral high-performance liquid chromatographic method for ketoprofen enantiomers
R Lovlin, M Vakily, F Jamali
Journal of Chromatography B: Biomedical Sciences and Applications 679 (1-2 …, 1996
Human pharmacokinetics of tiaprofenic acid after regular and sustained release formulations: lack of chiral inversion and stereoselective release
M Vakily, F Jamali
Journal of pharmaceutical sciences 83 (4), 495-498, 1994
S1095 the pharmacokinetics of TAK-390mr 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and lansoprazole 60 mg: a retrospective analysis
MD Mayer, M Vakily, G Witt, DJ Mulford
Gastroenterology 4 (134), A-176, 2008
Inclusion complexation of heptakis(2,6‐di‐o‐ethyl)‐β‐cyclodextrin with tiaprofenic acid: Pharmacokinetic consequences of a pH‐dependent release and …
M Vakily, FM Pasutto, M Daneshtalab, F Jamali
Journal of pharmaceutical sciences 84 (8), 1014-1019, 1995
The system can't perform the operation now. Try again later.
Articles 1–20